Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
Launched by WYETH IS NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · Dec 21, 2007
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
This study will require 6 months to be completed (3 months for nasopharyngeal samples collection; 3 months dor analysis). Each child will participate for a 1 day period.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy children between
- • 2 to 9 years old.
- • No history of antibiotic use prior 1 month of enrollment
- • No history of invasive pneumococcal disease
About Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer
Wyeth, now a wholly owned subsidiary of Pfizer, is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong legacy in the pharmaceutical industry, Wyeth focuses on discovering and delivering medicines that address significant medical needs across various therapeutic areas, including vaccines, biologics, and specialty pharmaceuticals. Leveraging Pfizer's extensive resources and expertise, Wyeth continues to drive scientific advancement and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Medical Monitor
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials